On Friday, the Vetr crowd downgraded its rating on Gilead Sciences, Inc. GILD from 3.5 stars (Buy), issued a week ago, to 3 stars (Hold). Crowd sentiment at the time of this writing was generally cautious, with 62 percent of Vetr user ratings bearish.
Earlier in the week, Gilead announced plans to acquire Kite Pharma Inc KITE. Since then, share price in the biotech has jumped by 13.5 percent to $83.75.
The announcement also garnered a fair amount of analyst attention. Argus' David Toung issued an upgrade on the stock from Hold to Buy on Thursday while, two days earlier, Robert Spingarn of Credit Suisse raised his price target on the stock from $79 to $85.
See how crowdsourced ratings could help you time the market.
Currently, the Vetr crowd's average price target on Gilead is up at $86.44, which is above the average analyst target price of $83.59. More than 2 percent of users are holding $GILD in their watch-lists.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.